Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

RHEUMATOLOGY IN PERSPECTIVE · RHEUMAVIEW

SJÖGREN’S · Treatments in development

New treatments for Sjögren: what stage are they at?

Research and country-specific access

A treatment headline usually leaves one question unanswered: could this help the problem that matters most to me? Several programs are advancing, but a promising mechanism, a positive trial and an approved medicine are different stages. This guide explains what each approach is trying to change and what remains uncertain. It is a dated research map, not a list of treatments suitable for everyone.

How to read a treatment headline

Ask four questions: which part of the immune system does it target, which health problem was studied, what results are available, and where is that exact use authorized? Approval for another disease does not mean approval for Sjögren. A Breakthrough Therapy designation helps a drug’s development and review; it is not permission to market it. [R43] “Phase III” means a later stage of testing, not a successful result. “Completed” does not mean that results have been published. “Active, not recruiting” means that the study continues but new participants are not being enrolled.

A full report gives more information than a company’s announcement of success. Even after approval, local supply and payment or insurance coverage are separate questions.

Back to contents ↑

Ianalumab: B-cell-directed treatmentPhase III published · regulatory review ongoing

Phase III published · regulatory review ongoing Status: Phase III results are published. They show a modest benefit for systemic disease activity— inflammation affecting the body’s organs and tissues. A clear benefit for dryness, fatigue and pain has not been established. [R45] Ianalumab blocks BAFF-R, a receptor that supports B cells, and reduces their numbers. B cells help drive the abnormal immune response in Sjögren. The NEJM report included 275 and 504 randomized participants in NEPTUNUS-1 and NEPTUNUS-2.

At week 48, monthly treatment lowered ESSDAI, the clinician’s score of systemic activity, by about 1.3 and 1.0 points more than placebo. These are average differences between groups. [R45] The ESSPRI symptom questionnaire and the SSSD symptom diary, both completed by patients, showed no statistically significant advantage. Neither did the proportion meeting the trial’s response criterion: an ESSDAI fall of at least 5 points. Less measured inflammation does not necessarily mean less daily discomfort. [R45] According to Novartis, as of November 19, 2026, the application to approve ianalumab for Sjögren’s disease is under FDA review.

Earlier company reports described priority review and submissions in the United States, Europe, China and Japan. Priority review and Breakthrough Therapy designation do not mean approval for Sjögren. [R55] [R43] [R51] [R52] A separate phase III study, THALASSA (NCT07621809), started in July 2026 for people with substantial symptoms. Its main question is whether mouth dryness improves at one year. The study center must confirm current recruitment and whether you meet its criteria. [R53]

Back to contents ↑

Dazodalibep: organs and symptoms are separate questionsSystemic benefit · separate symptom study ongoing

Systemic benefit · separate symptom study ongoing Status: Phase III OASIZ-301 showed a benefit for systemic activity; the separate OASIZ-303 symptom study is still ongoing. Dazodalibep remains investigational. [R46] Dazodalibep blocks CD40L, a signal through which immune cells activate one another. The November 11 OASIZ-301 report describes 648 randomized participants. At week 48, ESSDAI fell by 5.6 points with treatment every four weeks, 5.2 every twelve weeks and 3.8 with placebo. The extra reductions over placebo were 1.8 and 1.4 points, respectively; both were statistically significant.

The full fall in a treatment group is therefore not all an additional drug effect. [R46] The every-four-week regimen also improved patient-reported dryness compared with placebo. This report does not establish a separate benefit for pain or fatigue. Earlier phase II symptom findings remain useful background. OASIZ-303 asks a separate phase III question: does treatment help people whose main burden is severe symptoms despite low systemic activity? [R28] [R46]

Back to contents ↑

Telitacicept: China and the international programChina approval · availability depends on country

China approval · availability depends on country Status: Approved in China according to the manufacturer’s June 2026 disclosure; an international phase III program is ongoing. Availability and the authorized use differ by country. [R32] [R41] Telitacicept targets BAFF and APRIL, proteins that help B cells survive and mature. The aim is to reduce abnormal immune activity. The reported Chinese indication is for adults with active disease receiving conventional treatment. It does not establish approval for Sjögren in the United States or every other country. [R32] UPSTREAM SjD is a separate international phase III program, NCT07404865.

The registry checked for this revision lists recruitment, 250 planned participants and US sites. Participants must have anti-SSA antibodies and active disease; serious organ-threatening complications are excluded. These are study entry rules, not a test showing who is certain to benefit. A local center must confirm current availability and all eligibility criteria. [R41]

Back to contents ↑

Nipocalimab: lowering circulating IgGPhase II signal · phase III confirmation needed

Phase II signal · phase III confirmation needed Status: A phase II benefit has been reported; phase III confirmation is still needed. Nipocalimab is not an approved Sjögren treatment. [R33] [R41] Nipocalimab blocks FcRn, a recycling pathway that keeps IgG antibodies in the blood. Blocking it lowers these antibodies. DAHLIAS found a benefit for clinical disease activity with the higher dose in people with active disease and anti-Ro antibodies.

A lower antibody level alone does not prove that dryness, pain or fatigue will improve, or predict an individual person’s response. [R33] The phase III DAFFODIL study, NCT06741969, is active, not recruiting: it continues, but enrollment is closed. The record updated November 12, 2026 lists 655 enrolled participants and no posted phase III results. Older recruitment announcements should not be taken as evidence that new participants can join. [R41]

Back to contents ↑

Efgartigimod: why the phase III UNITY study stoppedUNITY stopped · treatment benefit not confirmed

UNITY stopped · treatment benefit not confirmed Status: The phase III UNITY study was stopped for futility, meaning it was unlikely to demonstrate the planned benefit. Efgartigimod is not an established treatment for Sjögren’s disease. [R47] Efgartigimod also acts on FcRn to reduce circulating IgG antibodies. The small RHO trial gave an encouraging early result on a combined measure of response, but did not formally test a statistical hypothesis. On October 8, 2026, argenx announced that an independent committee recommended stopping UNITY because it was unlikely to meet its main week-48 clinical disease-activity goal.

The reason was insufficient expected benefit; no new safety signal was reported. The early result therefore did not establish that the larger study would succeed. [R34] [R47] SERENITY (NCT07760818) is a separate phase II study for specific Sjögren-related polyneuropathies —conditions affecting multiple peripheral nerves. It is not a study for every kind of pain or tingling. The record updated November 19, 2026 lists recruitment and 75 planned participants. Check the current record and study center before considering participation. [R41]

Back to contents ↑

Other immune approaches: success is not guaranteedHCQ combinations · preliminary trial results

HCQ combinations · preliminary trial results Iscalimab targets CD40, involved in communication between immune cells. Remibrutinib targets BTK, part of signaling inside these cells. Their studies showed clearer benefits for systemic activity than for symptoms. A trial testing filgotinib, lanraplenib and tirabrutinib did not meet its main goal. A similar target does not make two drugs interchangeable. [R35] [R36] [R37] The NECESSITY trial tested hydroxychloroquine (HCQ) with mycophenolate mofetil or leflunomide.

Its ACR 2026 conference abstract reported a week-24 STAR response in about 54% with HCQ plus mycophenolate mofetil and 52% with HCQ plus leflunomide, compared with 24% on placebo. STAR combines several aspects of disease into one measure of response; these percentages do not mean that every symptom improved. These are preliminary conference findings. [R48] The clearest difference was in the group with substantial symptoms but low systemic activity. Results were inconclusive in the smaller group with more systemic activity and when a different combined measure, CRESS, was used.

Serious adverse events were more frequent in the HCQ–mycophenolate group. Discuss these findings with a rheumatologist; they do not justify starting or changing a combination on your own. [R48] The RepurpSS studies of leflunomide–HCQ and a small low-dose IL-2 trial are also part of the research picture. The practical question remains: which problem would treatment address, what benefit is realistic, and how will side effects be monitored? The choice depends on individual risks as well as potential benefit. [R23] [R24] [R38]

Back to contents ↑

CAR-T and other cell therapies

CAR-T uses immune T cells modified to recognize a chosen target. Some early cell-therapy studies include Sjögren among several severe autoimmune diseases. The planned total across all diagnoses is not the number of people with Sjögren already treated. A registry entry does not establish remission or cure. [R42] Different cell products, preparatory treatments and diseases carry different risks, including infections, immune reactions, neurological complications and long-term effects. Isolated success stories in other diseases do not show how these approaches compare with established care for Sjögren.

A study team should explain both what is known and what remains uncertain. [R42] On August 24, 2026, Novartis paused 8 rapcabtagene autoleucel (rap-cel) trials in autoimmune and neurological diseases. According to statements the company provided to journalists, 3 participants died from complications of IEC-HS, a severe inflammatory reaction. [R58] [R59] [R61] The pause included the study involving people with rheumatoid arthritis or Sjögren’s disease. The public reports do not identify the diagnoses of the 3 participants who died.

Novartis still listed recruitment as paused on November 19, 2026. [R55] [R57] [R59] BMS separately paused its zola-cel autoimmune program to review safety. On October 23, 2026, BMS reported a separate death from pneumonia with sepsis in a participant with multiple sclerosis after zola-cel and additional immune-suppressing treatment. BMS stated that this later death was not the reason for its earlier pause. [R58] [R60] [R62] The registry record lists the rap-cel study NCT07048197 as active, not recruiting. That label alone cannot show whether a safety pause has ended.

These reports concern specific products and programs; they do not establish the same risks or status for all cell therapies. Ask the study team about the current situation. [R56]

Back to contents ↑

Dryness treatments and gland repairCevimeline solution · FDA-approved for dry mouth

Cevimeline solution · FDA-approved for dry mouth Cevimeline oral solution is a new form of an existing dry-mouth medicine. The FDA approved liquid EVOXAC on October 15, 2026 for adults with Sjögren’s disease. It has the same active ingredient as the capsules and may help people who have difficulty swallowing them. The manufacturer expected US availability by the end of 2026; ask a pharmacist about current supply. [R49] [R50] This treats a symptom; it does not treat systemic inflammation or show that glands have regenerated. Cevimeline is unsuitable for some people, including those with uncontrolled asthma or certain eye conditions.

Discuss suitability, dosing and possible side effects with your clinician. [R54] Local eye or mouth treatments may improve moisture or surface health without changing the underlying autoimmune disease. More tears or saliva for a short time does not prove that gland tissue has regrown. [R39] The human aquaporin gene-transfer research discussed here concerns salivary damage after radiotherapy, not Sjögren. Its results cannot be presented as a Sjögren cure. Gene transfer, organoids grown in a laboratory, tissue engineering and different cell products are separate approaches at different research stages. [R40] [R41]

Back to contents ↑

How to consider joining a study

Find the study identifier and current registry entry, then contact the listed study center through its official route. Confirm whether that particular site is recruiting, what participation requires and who decides eligibility. A general “recruiting” label does not guarantee a place at your local center. [R41] [R44] Ask about random assignment to treatment or placebo and your usual care; visits and travel; medication changes; rescue treatment if you worsen; costs; requirements concerning contraception, pregnancy and family planning; your right to withdraw; and care after the study ends.

Participation may give access to an experimental therapy, but benefit is not guaranteed. This page does not collect patient information or enroll participants.

Back to contents ↑

What do the trial numbers mean for me?

An inflammation score can improve without a clear improvement in dryness, fatigue or pain. Ask which outcome changed, how much more it changed than with placebo, and whether the participants had problems similar to yours. An average difference between groups cannot predict exactly how much one person will improve. [R45] [R46] For OASIZ-301, the November results report identifies 648 randomized participants. That means they were assigned to study groups, not that all of them benefited. Earlier planned or registry counts describe different records and should not replace the reported randomized population.

A discrepancy needs an explanation from the source, not a guess. For your care, benefit, risks and eligibility matter more than a headline number. [R46]

Back to contents ↑

What news would matter most next?

The most useful news will explain the extra benefit over comparison care, effects on daily function, serious harms, longer follow-up and an actual approved indication in your country. Full phase III results matter more than a headline alone. A change in immune cells or antibodies is only one part of the evidence. Your current care still matters while research advances. Eye and dental protection, symptom treatment and appropriate organ care do not have to wait for a future medicine. The next chapter explains the biological mechanisms and why promising ideas sometimes succeed and sometimes fail.

Back to contents ↑

Sources

  1. [R23] van der Heijden et al. RepurpSS-I (2020)
  2. [R24] Wong et al. RepurpSS-II (2026)
  3. [R26] Bowman et al. Ianalumab phase 2b dose-finding trial (2022)
  4. [R27] Novartis: NEPTUNUS-1/2 phase III results presented at ACR (29 October 2025)
  5. [R28] St Clair et al. Dazodalibep phase II: two populations (2024)
  6. [R29] Amgen: OASIZ 301 positive topline announcement (22 September 2026)
  7. [R32] RemeGen statutory disclosure: telitacicept Sjögren indication approval (9 June 2026)
  8. [R33] DAHLIAS: nipocalimab phase II (Lancet 2025)
  9. [R34] Peene et al. Efgartigimod RHO proof-of-concept trial (2026)
  10. [R35] Fisher et al. Iscalimab TWINSS phase 2b (2024)
  11. [R36] Dörner et al. Remibrutinib LOUiSSE phase II (2024)
  12. [R37] Price et al. Filgotinib, lanraplenib and tirabrutinib phase II (2022)
  13. [R38] He et al. Low-dose interleukin-2 randomized trial (2022)
  14. [R39] Yokoi et al. Diquafosol tear-volume pilot in Sjögren dry eye (2016)
  15. [R40] AAV2-hAQP1 gene therapy for radiation-induced xerostomia, phase I (2026)
  16. [R41] ClinicalTrials.gov: named late-stage Sjögren programs
    Additional source recordshttps://clinicaltrials.gov/study/NCT05349214https://clinicaltrials.gov/study/NCT06104124https://clinicaltrials.gov/study/NCT06245408https://clinicaltrials.gov/study/NCT05673993https://clinicaltrials.gov/study/NCT07404865https://clinicaltrials.gov/study/NCT04968912https://clinicaltrials.gov/study/NCT06741969https://clinicaltrials.gov/study/NCT05817669https://clinicaltrials.gov/study/NCT07760818https://clinicaltrials.gov/study/NCT03905525https://clinicaltrials.gov/study/NCT04035668https://clinicaltrials.gov/study/NCT03100942https://clinicaltrials.gov/study/NCT02446249
  17. [R42] ClinicalTrials.gov: early cellular studies that list Sjögren disease
    Additional source recordshttps://clinicaltrials.gov/study/NCT06828042https://clinicaltrials.gov/study/NCT06821659https://clinicaltrials.gov/study/NCT06947473
  18. [R43] Novartis: FDA Breakthrough Therapy designation for ianalumab (16 January 2026)
  19. [R44] Sjögren Foundation: find a clinical trial
  20. [R45] NEPTUNUS-1/2: randomized phase III trials, NEJM (21 October 2026)
  21. [R46] Amgen: OASIZ-301 numerical phase III results (11 November 2026)
  22. [R47] argenx: phase III UNITY stopped for futility (8 October 2026)
  23. [R48] Mariette et al. NECESSITY: ACR 2026 abstract LB15
  24. [R49] FDA: EVOXAC oral solution approval letter, NDA 221183 (15 October 2026)
  25. [R50] Cosette: EVOXAC oral solution and expected US availability (20 October 2026)
  26. [R51] Novartis Q1 2026: ianalumab priority review and regulatory submissions (28 April 2026)
  27. [R52] Novartis: NEPTUNUS extension and pending regulatory review (10 November 2026)
  28. [R53] THALASSA: phase III ianalumab for high symptom burden, NCT07621809
  29. [R54] EVOXAC prescribing information, including oral solution (October 2026)
  30. [R55] Novartis: Meet Novartis Management presentation, November 19, 2026, slides 22, 25 and 26 — SjD under FDA review; rap-cel recruitment paused.
  31. [R56] ClinicalTrials.gov: rapcabtagene autoleucel in rheumatoid arthritis and Sjögren disease, NCT07048197
  32. [R57] Sjögren’s Foundation: statement on recent CAR-T clinical trial developments (2026)
  33. [R58] Published direct company statements: Novartis and BMS autoimmune CAR-T safety pauses. BioPharma Dive, August 31, updated September 1, 2026.
  34. [R59] Published Novartis statement and eight paused rap-cel protocols. Fierce Biotech, August 31, 2026.
  35. [R60] Bristol Myers Squibb: Breakfree-2 results and safety update in multiple sclerosis, October 23, 2026.
  36. [R61] Hines et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023;29:438.e1–438.e16.
  37. [R62] Interview with BMS Cell Therapy president Lynelle Hoch: later MS death and the earlier zola-cel pause are separate events. Fierce Biotech, October 26, 2026.

Personal educational publication by Olga Goodman, MD. This is not a clinic portal or an emergency service. Any private expert service is separate from clinic accounts and insurance billing. Reuse requires attribution and a link to the original publication.

dr.rheumaview.com · Olga Goodman, MD

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Clinical trialsInvestigational therapiesSjögren disease